These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22594140)

  • 1. Yellow fever vaccine-associated viscerotropic disease.
    Rowland M; Plackett TP; Smith R
    Mil Med; 2012 Apr; 177(4):467-9. PubMed ID: 22594140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [YEL-AND meningoencephalitis in a 4-year-old boy consecutive to a yellow-fever vaccine].
    Gerin M; Wroblewski I; Bost-Bru C; N'guyen MA; Debillon T
    Arch Pediatr; 2014 Apr; 21(4):384-7. PubMed ID: 24630625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
    Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
    J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inactivated cell-culture vaccine against yellow fever.
    Monath TP; Fowler E; Johnson CT; Balser J; Morin MJ; Sisti M; Trent DW
    N Engl J Med; 2011 Apr; 364(14):1326-33. PubMed ID: 21470010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
    van de Pol EM; Gisolf EH; Richter C
    J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow fever vaccine: worthy friend or stealthy foe?
    Seligman SJ; Casanova JL
    Expert Rev Vaccines; 2016 Jun; 15(6):681-91. PubMed ID: 27087465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong.
    Leung WS; Chan MC; Chik SH; Tsang TY
    J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27087559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.
    Douce RW; Freire D; Tello B; Vásquez GA
    Am J Trop Med Hyg; 2010 Apr; 82(4):740-2. PubMed ID: 20348528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yellow fever: the recurring plague.
    Tomori O
    Crit Rev Clin Lab Sci; 2004; 41(4):391-427. PubMed ID: 15487593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yellow fever: epidemiology and prevention.
    Barnett ED
    Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever vaccine. WHO position paper.
    World Health Organization
    Wkly Epidemiol Rec; 2003 Oct; 78(40):349-59. PubMed ID: 14569711
    [No Abstract]   [Full Text] [Related]  

  • 15. Yellow fever - prevention in travellers.
    Neilson AA; Mayer CA
    Aust Fam Physician; 2010 Aug; 39(8):570-3. PubMed ID: 20877751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.
    Belsher JL; Gay P; Brinton M; DellaValla J; Ridenour R; Lanciotti R; Perelygin A; Zaki S; Paddock C; Querec T; Zhu T; Pulendran B; Eidex RB; Hayes E
    Vaccine; 2007 Dec; 25(50):8480-5. PubMed ID: 18023511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prescription of Yellow Fever Vaccine: The Experience of the International Vaccination Centre of the Loures-Odivelas Health Centre Group].
    Martinho C; Lopes D; Bastos L; Esteves H
    Acta Med Port; 2018 Dec; 31(12):724-729. PubMed ID: 30684369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yellow fever vaccination and neurological complications.
    Bayão TS; Cupertino MDC; Gomes AP; Siqueira-Batista R
    Rev Soc Bras Med Trop; 2018; 51(5):723-724. PubMed ID: 30304289
    [No Abstract]   [Full Text] [Related]  

  • 20. Suspected YF-AND after yellow fever vaccination in Finland.
    Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
    J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.